Related Experiment Video
Updated: Apr 27, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
Shan Shan Chen1, Stephen L Seliger, Linda F Fried
1aUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania bVA Maryland Healthcare System and University of Maryland School of Medicine, Baltimore, Maryland cVA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
Purpose Of Review:
This review presents the role of combination therapy of renin-angiotensin-aldosterone system blockade on cardiovascular and kidney disease.
Recent Findings:
Three large randomized controlled trials comparing combination therapy of renin-angiotensin-aldosterone system blockade to monotherapy in individuals with increased cardiovascular risk, chronic kidney disease, or diabetic nephropathy have been reported. These trials - ONTARGET, ALTITUDE, and VA NEPHRON-D - demonstrated an excess risk of adverse effects [especially acute kidney injury (AKI) and hyperkalemia] with combination therapy, without significant benefit in reducing cardiovascular and renal morbidity.
Summary:
Current evidence supports avoiding dual renin-angiotensin-aldosterone system blockade in patients with chronic kidney disease. Subsequent studies of dual renin-angiotensin-aldosterone system blockade should examine adverse event risks and renal progression endpoints.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hormonal Regulation
Hypertension II: Pathophysiology

